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dinucleotide-binding site in mice. A mutation (TGG to TGA)
in C57BL/6, which would result in deletion of the signal
peptide and of ﬂavin adenine dinucleotide-binding domain,
was previously discussed.3 Such a mutation may exit, and
may signiﬁcantly affect renalase function in C57BL/6 mice.
However, as the renalase KO mice is on a mixed genetic
background, the C57BL/6 background would, if anything,
reduce the severity of the observed phenotype.
In the absence of nicotinamide adenine dinucleotide,
renalase metabolizes epinephrine at a low rate as we prev-
iously reported.4 As shown in Figure 1, nicotinamide adenine
dinucleotide increases the rate of epinephrine metabolism by
18-fold (manuscript submitted). As Pandini et al.5 did not
include nicotinamide adenine dinucleotide in the reaction
assay, it is not surprising that they did not detect renalase’s
amine oxidase activity.
In summary, renalase is a secreted ﬂavin adenine dinu-
cleotide/nicotinamide adenine dinucleotide-dependent amine
oxidase that metabolizes catecholamines, and has an impor-
tant role in the regulation of blood pressure and cardiac
function.
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Angiotensin II-induced
phosphorylation of the
sodium chloride cotransporter
To the Editor: We read with interest the article by van der
Lubbe et al.,1 which investigated the effect of angiotensin II (Ang
II) on the regulation of sodium chloride transporter (NCC) in
the distal convoluted tubules. From the experimental results
using adrenalectomized animals, the authors concluded that Ang
II increased the total and phosphorylated NCC independently of
aldosterone. Although the results indicated that Ang II affected
NCC independently of circulating aldosterone, there still
remains a possibility that Ang II could have affected NCC by
the local aldosterone synthesized in the kidney.2
Although controversial, aldosterone could be synthesized
by extra-adrenal tissues including the kidney.2 Therefore, the
Ang II-induced effect on NCC in the adrenalectomized
animals could have been mediated by the local aldosterone
synthesized in the kidney. Local renal aldosterone, which was
increased by administration of Ang II, could have activated
kinases and then increased the phosphorylation and plasma
membrane abundance of NCC. Experiments with either an
aldosterone synthase inhibitor or a mineralocorticoid receptor
antagonist could clarify whether the effect of Ang II admin-
istration on NCC is mediated by local renal aldosterone.3,4
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Figure 1 |Renalase is a nicotinamide adenine dinucleotide
(NADH)-dependent amine oxidase. Rate of resazurin reduction
provides an indirect measure of renalase oxidase activity.
Renalase¼ 20mg recombinant renalase; epinephrine¼ 20 mmol/l;
NADH¼ 250 mmol/l. Fluorescence intensity measured using a
fluorescence plate reader (560 nm excitation filter, 590 nm
emission filter) at 37 1C, and recorded for 20min (n¼ 3).
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